Antares Pharma Inc (NASDAQ:ATRS) Expected to Announce Earnings of -$0.02 Per Share

Equities research analysts expect Antares Pharma Inc (NASDAQ:ATRS) to announce ($0.02) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for Antares Pharma’s earnings, with estimates ranging from ($0.04) to ($0.01). Antares Pharma posted earnings per share of ($0.01) in the same quarter last year, which suggests a negative year-over-year growth rate of 100%. The company is expected to report its next quarterly earnings results on Tuesday, November 5th.

According to Zacks, analysts expect that Antares Pharma will report full year earnings of ($0.08) per share for the current financial year, with EPS estimates ranging from ($0.10) to ($0.05). For the next financial year, analysts forecast that the business will report earnings of $0.16 per share, with EPS estimates ranging from $0.00 to $0.28. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that follow Antares Pharma.

Antares Pharma (NASDAQ:ATRS) last posted its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported ($0.01) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.04) by $0.03. The firm had revenue of $28.43 million during the quarter, compared to the consensus estimate of $21.66 million. Antares Pharma had a negative return on equity of 9.67% and a negative net margin of 4.03%.

ATRS has been the subject of a number of analyst reports. HC Wainwright restated a “buy” rating and issued a $4.50 price target on shares of Antares Pharma in a research note on Monday, May 6th. BidaskClub upgraded Antares Pharma from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $4.83.

ATRS stock traded down $0.12 during mid-day trading on Thursday, reaching $3.12. The company had a trading volume of 663,380 shares, compared to its average volume of 1,024,493. The company has a debt-to-equity ratio of 1.01, a current ratio of 3.46 and a quick ratio of 2.87. The stock has a 50 day simple moving average of $3.21 and a two-hundred day simple moving average of $3.10. The company has a market capitalization of $508.75 million, a price-to-earnings ratio of -78.00 and a beta of 0.95. Antares Pharma has a 52 week low of $2.53 and a 52 week high of $3.96.

Several hedge funds and other institutional investors have recently modified their holdings of the company. BNP Paribas Arbitrage SA lifted its holdings in Antares Pharma by 54,541.8% during the 1st quarter. BNP Paribas Arbitrage SA now owns 30,053 shares of the specialty pharmaceutical company’s stock worth $91,000 after purchasing an additional 29,998 shares during the last quarter. Searle & CO. acquired a new stake in Antares Pharma during the 1st quarter worth approximately $61,000. Perkins Capital Management Inc. lifted its holdings in Antares Pharma by 7.8% during the 1st quarter. Perkins Capital Management Inc. now owns 441,000 shares of the specialty pharmaceutical company’s stock worth $1,336,000 after purchasing an additional 32,000 shares during the last quarter. Mercer Global Advisors Inc. ADV acquired a new stake in Antares Pharma during the 1st quarter worth approximately $123,000. Finally, Enterprise Bank & Trust Co acquired a new stake in Antares Pharma during the 1st quarter worth approximately $45,000. Institutional investors own 43.10% of the company’s stock.

Antares Pharma Company Profile

Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

Recommended Story: Trading Stocks – What are percentage gainers?

Get a free copy of the Zacks research report on Antares Pharma (ATRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.